This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019 Oct 8;93(15):655-656.

doi: 10.1212/WNL.0000000000008238. Epub 2019 Sep 12.

Dosing interval of natalizumab in MS: Do good things come to those who wait?

David B Clifford¹, Kenneth L Tyler²

Affiliations

Affiliations

¹ From the Department of Neurology (D.B.C.), Washington University in St Louis, MO; and Department of Medicine and Immunology-Microbiology (K.L.T.), University of Colorado School of Medicine, Aurora. clifforddb@wustl.edu.
² From the Department of Neurology (D.B.C.), Washington University in St Louis, MO; and Department of Medicine and Immunology-Microbiology (K.L.T.), University of Colorado School of Medicine, Aurora.

PMID: 31515289
DOI: 10.1212/WNL.0000000000008238

Editorial

Dosing interval of natalizumab in MS: Do good things come to those who wait?

David B Clifford et al. Neurology. 2019.

. 2019 Oct 8;93(15):655-656.

doi: 10.1212/WNL.0000000000008238. Epub 2019 Sep 12.

Authors

David B Clifford¹, Kenneth L Tyler²

Affiliations

¹ From the Department of Neurology (D.B.C.), Washington University in St Louis, MO; and Department of Medicine and Immunology-Microbiology (K.L.T.), University of Colorado School of Medicine, Aurora. clifforddb@wustl.edu.
² From the Department of Neurology (D.B.C.), Washington University in St Louis, MO; and Department of Medicine and Immunology-Microbiology (K.L.T.), University of Colorado School of Medicine, Aurora.

PMID: 31515289
DOI: 10.1212/WNL.0000000000008238

No abstract available

PubMed Disclaimer

Comment on

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, Goldberg JD, Li X, Riddle E, Smirnakis K, Kasliwal R, Ren Z, Hotermans C, Ho PR, Campbell N. Ryerson LZ, et al. Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12. Neurology. 2019. PMID: 31515290 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information